目的 研究埃索美拉唑在支气管哮喘合并胃食管返流(GERD)病患者中的临床治疗效果。方法 将2015年6月至2016 年1月确诊的60例哮喘合并GERD患者按入院的先后顺序分为两组各30人，观察组患者口服埃索美拉唑肠溶片。对 照组患者口服奥美拉唑肠溶片,疗程6周。记录服药前后病人支气管哮喘评分，胃食管反流病评分以及临床疗效情 况。结果 两组患者经不同治疗方法治疗后，观察组患者的支气管哮喘评分以及胃食管反流病评分均显著低对照组 (2.00±0.50)分 vs (3.00±0.70)分，(1.50±0.70)分vs (2.00±0.80)分，观察组患者的总有效率(93.33%)显著 高于对照组患者(66.67%)，差异具有统计学意义(P＜0.05)。结论 埃索美拉唑在支气管哮喘合并胃食管返流病患者 的治疗中，并发症较少，效果显著，值得临床推广。

Objective To study the clinical treatment effect of esomeprazole in bronchial asthma combined with gastroesophageal reflux disease (GERD). Methods From June 2015 to January 2016, 60 cases of asthma combined with GERD were selected as study objects, which were divided into observation group and control group with 30 cases in each group according to admission order number, observation group patients were given oral esomeprazole enteric-coated metformin hydrochloride, while the control group patients were given oral omeprazole enteric-coated metformin hydrochloride in six weeks treatment. The bronchial asthma score before and after treatment, gastroesophageal reflux disease score and clinical curative effect were observed and recorded. Results After the different treatments, the bronchial asthma score and gastroesophageal reflux disease score of observation group were lower than those of control group (2.00±0.50) point vs (3.00±0.70) point, (1.50±0.70) point vs (2.00±0.80) point, the total effective rate of observation group was significantly higher than that of control group(93.33% vs 66.67%) , the differences were statistical significant (P<0.05). Conclusion Esomeprazole has fewer complications and significant effect in the treatment of bronchial asthma combined with gastroesophageal reflux disease, which is worthy of clinical expansion.